patients administered with therapeutic drug of nontuberculous mycobacterium
Conditions
Interventions
None listed
Sponsors
Center for Infectious Disease and Infection Control
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who were given EB, CAM, RFP judged that administration was necessary by a chief physician
Exclusion criteria
Exclusion criteria: (1) It is the patient with a history of the drug allergy in EB, CAM, RFP (2) HIV infection therapeutic drug (indinavir sulfate ethanol addition, saquinavir mesilate, nelfinavir mesilate, L biTaegu rabbi a type of radical preparation including), voriconazole, praziquantel, Tadalafil, terra pre-building, Japanese hawfinch pre-building sodium, pimozide, ergotamine component preparation, the patients receiving etc., (3) In the patients with impaired liver or kidney, it is the patient receiving the colchicine (4) The patients with biliary tract obstruction or the serious liver damage (5) Optic neuritis, patients with diabetes, patients with alcoholism (6) For an infection related to this medicine insusceptibility pathogen or resistant strain, it is the patient who is judged clinically when it is hard to expect an effect with this medicine (7) Pregnant woman, the patients nursing, the patients who may be pregnant (8) In addition, the patients who judged that it was inadequate as an object of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study for personalized medicine with therapeutic drug of nontuberculous mycobacterium | — |
Countries
Japan
Contacts
Public ContactOsamu Iketani
Center for Infectious Disease and Infection Control Center for Infectious Disease and Infection Control
Outcome results
None listed